According to recent figures published by the Spanish Society of Medical Oncology (SEOM), more than 30,000 new cases of lung cancer will be diagnosed in Spain in 2023, making it the second most frequent type of cancer in this ...
Mar 17, 2023
0
13
There is currently no drug for treating non-alcoholic fatty liver disease, which affects many people with type 2 diabetes and which can result in other serious liver diseases. A study led by researchers from Karolinska Institutet ...
Feb 3, 2023
0
82
Researchers at the Hong Kong University of Science and Technology (HKUST) developed a novel technology which allows genomic DNA and RNA sequencing to be carried out simultaneously in single cells of both frozen and fresh ...
Feb 2, 2023
0
22
It is a challenging feat to launch a new drug in the market, given the low probability of success during the research and development (R&D) phase and the high costs involved. In recent times, industry trends in external innovation ...
Jan 24, 2023
0
3
Bone loss is a part of aging that compromises quality of life and movement in many older people, but regenerative treatments to improve their health and well-being have been limited. Now, a study led by Lankenau Institute ...
Jan 19, 2023
0
64
In research published in Nature Medicine today, AI biotech company Owkin has demonstrated for the first time that federated learning (FL) can be used to train deep learning models on data from multiple hospitals on histopathology ...
Jan 19, 2023
0
4
For generations people have associated the terms "lab rat" and "guinea pig" with scientific research. Animal testing remains a standard and has been required for drug approval.
Jan 16, 2023
0
55
Collaborative research between University of Galway and Brunel University London has found that patients with severe and complicated obesity respond differently to a dietary weight loss program based on their genes.
Jan 5, 2023
0
2
Dr. Niklas Klümper, resident at the Clinic for Urology and working group leader at the Institute for Experimental Oncology at the University Hospital Bonn (UKB), is investigating which patients with metastatic bladder cancer ...
Dec 30, 2022
0
17
Patients with localized, hormone receptor-positive, HER2-low breast cancer treated with trastuzumab deruxtecan (T-DXd, Enhertu) in the neoadjuvant setting had an overall response rate of 75 percent in the absence of anastrozole ...
Dec 7, 2022
0
2
